Overview

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects

Status:
Recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

The study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Oral AL01211 in healthy volunteers and autosomal dominant polycystic kidney disease subjects

Phase:

Phase 1

Details

Lead Sponsor:

AceLink Therapeutics, Inc.

Collaborator:

Novotech (Australia) Pty Limited